Tag: Peregrine Pharma

Finance

Biotech Gainers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Northwest Biotherapeutics (NASDAQ:NWBO), Peregrine Pharmaceuticals (NASDAQ:PPHM), Dyax (NASDAQ:DYAX)

Trade-Ideas LLC identified Inovio Pharmaceuticals Inc (NYSEMKT:INO) as a “barbarian at the gate” (strong stocks crossing above resistance with today’s range greater than 200%) candidate. Inovio Pharmaceuticals, Inc. (NYSEMKT:INO), together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Currently there are 3 analysts that rate Inovio Pharmaceuticals Inc (NYSEMKT:INO) a buy, no … Continue reading Biotech Gainers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Northwest Biotherapeutics (NASDAQ:NWBO), Peregrine Pharmaceuticals (NASDAQ:PPHM), Dyax (NASDAQ:DYAX)

Kristen Barton
FB Nasdaq FB Facebook
Finance

Healthcare Active Stocks: Peregrine Pharmaceuticals (NASDAQ:PPHM), Merck & Co (NYSE:MRK), Teva Pharmaceutical Industries (NYSE:TEVA), Abbott Laboratories (NYSE:ABT)

Shares of Peregrine Pharmaceuticals (NASDAQ: PPHM ) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer, dipped as much as 11% after reporting its third-quarter earnings results. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was -8.05% in last session and finished the day at $2.40. Traded volume was 14.14million shares in the last session and the average volume of the stock remained 4.31million shares. … Continue reading Healthcare Active Stocks: Peregrine Pharmaceuticals (NASDAQ:PPHM), Merck & Co (NYSE:MRK), Teva Pharmaceutical Industries (NYSE:TEVA), Abbott Laboratories (NYSE:ABT)

Mark Doerr
Finance

Biotech Decliners: Peregrine Pharmaceuticals (NASDAQ:PPHM), CytRx Corporation (NASDAQ:CYTR), PTC Therapeutics (NASDAQ:PTCT), Amicus Therapeutics (NASDAQ:FOLD)

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced its earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was -8.05% in last session and finished the day at $2.40. Traded volume was 14.14million shares in the last session and the average volume of the stock remained 4.31million shares. The beta of the … Continue reading Biotech Decliners: Peregrine Pharmaceuticals (NASDAQ:PPHM), CytRx Corporation (NASDAQ:CYTR), PTC Therapeutics (NASDAQ:PTCT), Amicus Therapeutics (NASDAQ:FOLD)

Kristen Barton
BioTech

Biotech Active Stocks: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Rexahn Pharmaceuticals (NYSEMKT:RNN), Peregrine Pharmaceuticals (NASDAQ:PPHM)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) raises $63 million, secures capital needs for near-term trial advancement and preparation to enter Phase lll studies. Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -1.96 percent to $3.51 yesterday on volume of INO 6.88million shares. The intra-day range of the stock was $3.50 to $3.71. Inovio Pharmaceuticals Inc (NYSEMKT:INO) has a market capitalization of $795.32million. After announcing two years ago that it would … Continue reading Biotech Active Stocks: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Rexahn Pharmaceuticals (NYSEMKT:RNN), Peregrine Pharmaceuticals (NASDAQ:PPHM)

Richard Atkins
BioTech

Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Peregrine Pharmaceuticals (NASDAQ:PPHM) is scheduled to be releasing its Q314 earnings data on Friday, March 7th. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was 47.64% in last session and finished the day at $2.82. Traded volume was 36.76million shares in the last session and the average volume of the stock remained 3.12million shares. The beta of the stock remained 1.40. Peregrine Pharmaceuticals (NASDAQ:PPHM) insider ownership is 16%. … Continue reading Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Colin Pettis